Motley Fool  Dec 8  Comment 
Fitbit, Ariad Pharmaceuticals, and Trex Company may all be poised to deliver significant returns to investors.
Benzinga  Dec 7  Comment 
Sen. Bernie Sanders and President-elect Donald Trump don't agree on much, but they seem to have found some middle-ground when it comes to drug prices. Sanders said in a press release Tuesday that he proposed an amendment that would lower the...
GenEng News  Dec 6  Comment 
Data from a Phase III study evaluating Novartis’ selective anaplastic lymphoma kinase (ALK) gene inhibitor, Zykadia® (ceritinib), showed that first-line treatment with the drug resulted in a 45% reduction in the risk of disease progression in...
SeekingAlpha  Dec 5  Comment 
Motley Fool  Dec 2  Comment 
Post-election optimism that regulators will dial back rhetoric regarding drug prices rekindled investors' interest last month.
newratings.com  Nov 29  Comment 
WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals Inc. (ARIA) announced that the U.S. Food and Drug Administration has granted Iclusig (ponatinib) full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase...
Benzinga  Nov 25  Comment 
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday’s regular...
Benzinga  Nov 17  Comment 
$14.34 - October 10 high $14.26 - September 28 high $14.14 - Intraday high as of 12:22 PM $14.00 - Current price as of 12:22 PM $13.10 - Intraday low as of 12:22 PM $12.87 - Wednesday close If content like this is...


Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki